Event Overview - Research Frontiers Inc and Gauzy are showcasing SPD-SmartGlass technology at the 2024 CES show in Las Vegas, with Gauzy located at Booth 6516 in Automotive West Hall [1] - The event is expected to attract 150,000 attendees, who are invited to visit the Gauzy booth to see the latest developments and products using SPD-SmartGlass technology [1] Press Briefing and CEO Participation - A press briefing will be conducted by Research Frontiers and Gauzy on Thursday, with events for customers earlier in the week [2] - Eyal Peso, CEO of Gauzy, and Joe Harary, CEO of Research Frontiers Inc, will be present at Gauzy’s Booth 6516 on January 9 at 11am ET [2] Market and Industry Insights - The global smart glass market was estimated at $6 6 billion in 2023 and is expected to grow at a CAGR of 9 9% from 2023 to 2030 [3] - Smart glass technology is disrupting multi-billion-dollar industries such as aeronautics, automotive, and architecture [3] - Leading automotive manufacturer Ferrari has installed SPD Smart Glass in its top-selling SUV model [3] Applications and Benefits of Smart Glass - Smart glass allows passengers to control light in aircraft cabins through the touch of a button [3] - The technology is transforming built spaces from design to sustainability, advancing sustainability mandates for OEMs, property owners, and end-users [3] - Smart glass can change from transparent to opaque in milliseconds, enhancing the experience of light in various environments [4] Interactive Experience at CES - Attendees can meet the CEOs of Gauzy and Research Frontiers, who are behind the patents, production, and delivery of SPD Smart Glass [4] - The booth will showcase real-life applications of smart glass in smart buildings, homes, retrofit and new architectural construction, automotive, aircraft, and trains [4]

Research Frontiers Incorporated (NASDAQ:REFR) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Harary - President and CEO Operator Good afternoon, ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the Third Quarter of 2024 Results of Operations and Recent Developments [Operator Instructions]. This conference is being recorded today. A replay of this conference call will be available starting later today in the Investors section o ...

Licensing Fee Income - The Company's licensing fee income for Q3 2024 was $354,408, a 116% increase from $164,146 in Q3 2023, driven by higher royalties from the automotive and aircraft markets [56]. - For the nine months ended September 30, 2024, licensing fee income reached $1,157,380, up 94% from $597,362 in the same period of 2023, attributed to increased royalties from automotive, aircraft, and architectural markets [62]. Operating Expenses and Net Loss - Operating expenses decreased by $87,769 to $454,866 in Q3 2024 from $542,635 in Q3 2023, mainly due to lower credit loss expenses and reduced marketing costs [57]. - The Company's net loss for Q3 2024 was $166,816 ($0.00 per share), an improvement from a net loss of $472,166 ($0.01 per share) in Q3 2023 [61]. Research and Development - Research and development expenditures for Q3 2024 were $131,246, a slight decrease from $135,319 in Q3 2023 [58]. Other Income and Cash Position - The Company recorded $35,152 in other income for Q3 2024 related to an Employee Retention Credit under the CARES Act [60]. - As of September 30, 2024, the Company had cash and cash equivalents of approximately $1.6 million and working capital of $2.7 million [68]. Future Projections - The projected quarterly cash flow shortfall for the next 12 months is estimated to be between $200,000 and $250,000, with potential for expense reductions [69]. - The Company expects to fund its operations for more than the next five years with current cash and cash equivalents, although future financing may be required [70]. - The automotive market is anticipated to be the largest source of royalty income for the Company over the next several years, influenced by various industry trends [51].

WOODBURY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced today that it will release its third quarter 2024 financial results on Thursday, November 7, 2024. Research Frontiers will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 7, 2024 to discuss its third quarter 2024 financial and operating results, as well as recent developments. Who: Joseph M. Harary, President & CEODate/Time: Thursday, November 7, 2024, 4:30 PM ETDial-in Information: 1-888- ...

Core Insights - Sutro Biopharma has initiated the REFRαME-P1 study for luveltamab tazevibulin (luvelta) targeting pediatric patients with CBFA2T3::GLIS2 acute myeloid leukemia (AML) [1][4] - The trial aims to address a significant unmet need in treating a rare and aggressive form of leukemia in infants and toddlers [2][3] - Luvelta has shown promising results in previous compassionate use cases, with a 42% complete remission rate in pediatric patients [2][3] Company Overview - Sutro Biopharma is a clinical-stage oncology company focused on developing site-specific antibody-drug conjugates (ADCs) [1][8] - The company utilizes its proprietary XpressCF® platform for the development of its therapeutics, including luvelta [6][8] - Sutro has multiple clinical-stage candidates and is engaged in various trials for different cancer types, including ovarian and endometrial cancers [6][8] Clinical Development - The REFRαME-P1 study is a global registration-enabling trial for luvelta in children under 12 years with CBF/GLIS AML [4] - The study is expected to have most sites operational by the end of 2024 [4] - Luvelta has received Fast Track designation from the FDA for ovarian cancer and Orphan and Rare Pediatric Disease designations for CBF/GLIS pediatric AML [7]

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novelformat antibody drug conjugates (ADCs), today announced that REFRαME-L1, the global Phase 2 study of luveltamab tazevibulin (luvelta) for patients with non-small cell lung cancer (NSCLC) whose tumor expresses Folate Receptor-α (FRα), has been initiated and is open for enrollment. Initial data from this study is expecte ...

Research Frontiers, Inc. (NASDAQ:REFR) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Joe Harary - President & CEO Conference Call Participants Neal Goldman - Goldman Capital Management Michael Kay - Kay Associates Leonard Lietzow - Private Investor Jeff Harvey - Private Investor Allen Ginsberg - Private Investor Operator Good afternoon ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the Second Quarter of 2024 results of operations ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) of THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarter ended June 30, 2024 Commission File Number 000-14893 RESEARCH FRONTIERS INCORPORATED (Exact name of registrant as specified in its charter) DELAWARE 11-2103466 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 240 CROSSWAYS PARK DRIVE WOODBURY, NEW YORK 11797-2033 (Addr ...

WOODBURY, N.Y., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (NASDAQ:REFR) announced its financial results for its second quarter of 2024. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments. • Who: Joseph M. Harary, President & CEO • Date/Time: Thursday, August 1, 2024, 4:30 PM ET • Dial-in Information:1-888-334-5785 • Replay: Available on Friday, August 2, 2024 for 90 days at https://smartglass-ir ...

WOODBURY, N.Y., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its second quarter of 2024. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments. • Who: Joseph M. Harary, President & CEO • Date/Time: Thursday, August 1, 2024, 4:30 PM ET • Dial-in Information:1-888-334-5785 • Replay: Available on Friday, August 2, 2024 for 90 days at https://smartglass-i ...